Tatsuki Ikuse

Tatsuki Ikuse

Auto-generated profile, based on publicly available information

Tatsuki Ikuse

Division of Infectious Diseases, National Center for Child Health and Development

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2021 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
TITatsuki Ikuse
Tatsuki Ikuse
YAYuta Aizawa
Yuta Aizawa
HTHayato Takihara
Hayato Takihara
SOShujiro Okuda
Shujiro Okuda
KWKanako Watanabe
Kanako Watanabe
ASAkihiko Saitoh
Akihiko Saitoh
Enterovirus D68 (EV-D68) causes a range of clinical manifestations, including asthma-like illness, severe respiratory disease, and acute flaccid myelitis. EV-D68 has caused worldwide outbreaks since 2014 and is now recognized as a reemerging infection in many countries.

2 March 2023 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
TITatsuki Ikuse
Tatsuki Ikuse
YAYuta Aizawa
Yuta Aizawa
TYTakayuki Yamanaka
Takayuki Yamanaka
SHSatoshi Hasegawa
Satoshi Hasegawa
THTakanori Hayashi
Takanori Hayashi
ASAkihiko Saitoh
Akihiko Saitoh
Background: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has dramatically altered the clinical profile of pediatric coronavirus disease 2019 (COVID-19). In Japan, we experienced a pandemic of omicron subvariant BA.1/BA.2 from January through June 2022. However, after the emergence of BA.5 in early July 2022, the number of children hospitalized with COVID-19 increased dramatically in Japan. Methods: We collected data on monthly numbers of cases and clinical characteristics of hospitalized children with COVID-19 in 13 hospitals, the total number of pediatric COVID-19 cases, and COVID-19 vaccination rates in Niigata, Japan, for the period from January 2020 through August 2022. We compared clinical presentation during the periods of BA.1/BA.2 predominance (January–June 2022) and BA.5 predominance (July–August 2022) and estimated vaccine effectiveness (VE) against hospitalization during the BA.5-predominant period. Results: Between January 1, 2020, and August 31, 2022, 49,387 children (19,085 children/100,000 population) were newly diagnosed as having COVID-19, and 393 were hospitalized for COVID-19. Hospitalization for febrile seizure, especially complex seizure, was significantly higher during BA.5 predominance than during BA.1/BA.2 predominance (27.9% vs. 7.0%, P < 0.01). VE against hospitalization during BA.5 predominance was estimated to be 75% (95% confidence interval, 48%–88%, P < 0.01). Conclusions: The emergence of BA.5 significantly affected children in Japan; the number with complex febrile seizure who required hospitalization was higher than during BA.1/BA.2 predominance. The COVID-19 vaccination rate in children must be increased to prevent hospitalization for COVID-19 and to prepare for current and future variant outbreaks.

21 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RSReiko Shimbashi
Reiko Shimbashi
BCBin Chang
Bin Chang
YTYoshinari Tanabe
Yoshinari Tanabe
HTHiroaki Takeda
Hiroaki Takeda
HWHiroshi Watanabe
Hiroshi Watanabe
AGAdult IPD Study Group
Adult IPD Study Group
Enhanced surveillance of invasive pneumococcal disease (IPD) in adults was conducted during April 2013–March 2018 in 10 of 47 prefectures in Japan, and a total of 1277 IPD patients were enrolled. An emergence of IPD caused by serotype 12F was identified during May 2015–March 2018 through this surveillance. 12F isolates were composed of four related sequence types. In total, 120 patients with 12F IPD were reported during this period. To characterize the clinical features of 12F IPD, the disease characteristics of these patients were compared with those of 1157 patients with non-12F IPD. Compared with the non-12F IPD patients, a significantly lower proportion of 12F IPD patients was aged 65 years or older (55% vs. 70%), vaccinated with 23-valent pneumococcal polysaccharide (4% vs. 14%), had comorbid illness (65% vs. 77%), or were immunocompromised (19% vs. 30%; all P < 0.05). No significant difference in the proportion of case fatalities was found between the two groups. The proportions of those aged 65 years or older (53% vs. 69%) and with bacteremic pneumonia (35% vs. 69%) were significantly lower in 17 patients who died from 12F IPD than in 205 patients who died from non-12F IPD (all P < 0.05). Differences in clinical features were similarly found between 12F IPD patients and patients in low- or intermediate-level invasive potential serogroups. Our data demonstrated that serotype 12F was associated with IPD in younger adults and a lower proportion of comorbid illness, including immunocompromised conditions, in adult IPD, suggesting the high invasive potential of the serotype 12F. In addition, patients who died from 12F IPD were younger and had proportionately more bacteremia without focus. These findings may provide new insight into the pathogenesis of IPD in adults caused by 12F serotype with a high invasive potential.

11 September 2020 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
TITatsuki Ikuse
Tatsuki Ikuse
YAYuta Aizawa
Yuta Aizawa
TYTakayuki Yamanaka
Takayuki Yamanaka
RHRie Habuka
Rie Habuka
KWKanako Watanabe
Kanako Watanabe
ASAkihiko Saitoh
Akihiko Saitoh
Background: Enterovirus D68 (EV-D68) causes asthma-like respiratory infection in children. Several EV-D68 outbreaks have been reported worldwide since the largest outbreak occurred in the United States in 2014. We experienced an accumulation of pediatric cases with asthma-like respiratory illness in Niigata, Japan, in 2018. Study design: To determine whether EV-D68 was responsible for the case accumulation, this prospective observational study evaluated children hospitalized in 1 of 8 hospitals with asthma-like respiratory illness in Niigata, Japan, during October and November 2018. Diagnoses were made by EV-D68–specific RT-PCR using nasopharyngeal samples. The clade was identified by sequence analyses, and a phylogenetic tree was created. To evaluate seasonal variation, data from pediatric cases with asthma-like respiratory illness in 2018 were retrospectively analyzed. Results: In 2018, 114 children were hospitalized with asthma-like respiratory illness in October and November, and 47 nasopharyngeal samples were collected. EV-D68 was detected in 22/47 (47%) patients during the study period. The phylogenetic tree revealed that all strains belonged to the clade B3 branch, which has been detected worldwide every 2 years since 2014. Conclusions: EV-D68 was the associated pathogen for asthma-like respiratory illness in children in Japan in 2018. Clade B3, the dominant clade in outbreaks worldwide, was responsible for the outbreak. Detection and detailed virologic analysis of EV-D68 is important as part of worldwide surveillance, as it will aid in understanding the epidemiologic characteristics of EV-D68 infection.

2 August 2018 in Epidemiology and Infection
Verified
Journal Article
Closed access
PDF file
TIT. Ikuse
T. Ikuse
RHR. Habuka
R. Habuka
YWY. Wakamatsu
Y. Wakamatsu
TNT. Nakajima
T. Nakajima
NSN. Saitoh
N. Saitoh
ASA. Saitoh
A. Saitoh
Pneumococcal serotype replacement is an important issue after the introduction of pneumococcal conjugate vaccine (PCV) in children. After the introduction of 13-valent PCV, the incidence of invasive pneumococcal diseases (IPD) caused by Streptococcus pneumoniae serotype 12F (Sp12F) have increased in some countries; however, an outbreak of Sp12F has not reported in the post-13-valent PCV era. We experienced a local outbreak of Sp12F during March through May 2016 in Tsuruoka city, Japan after the introduction of 13-valent PCV in 2013. The IPD patients were two children and seven adults, three of whom died with a rapid disease progress. Although the clear transmission route was not determined, eight of the nine patients (89%) had close contact with children, which suggests that transmitted colonisation of Sp12F among children and adults might be the source of transmission. Continuous monitoring of IPDs, along with the determination of pneumococcal serotypes, is warranted in the post–13-valent PCV era. New IPD control strategies may be needed if this fatal outbreak continues to occur.

9 January 2025 in Eurosurveillance
Verified
Journal Article
Open access
TITatsuki Ikuse
Tatsuki Ikuse
TMToshihiro Matsui
Toshihiro Matsui
KSKensuke Shoji
Kensuke Shoji
NKNaoko Kono
Naoko Kono
MYMasaki Yamada
Masaki Yamada
TITakashi Igarashi
Takashi Igarashi
In 2022–23, several European countries reported paediatric acute liver failure (ALF) with enterovirus infection. In August–November 2024, three neonatal cases of ALF with echovirus 11 (E11) were reported in Tokyo, Japan. All neonates developed irreversible multiple-organ failure and died. The E11 strain belonged to the new lineage 1, which was the same as strains isolated from neonatal ALF cases in Europe in 2022–23.